I like PFE. It dropped off my list this coming year based on weakness in ttm earnings. Earnings look to be improving, however. Long term growth, however, may not be super-attractive. I'm bullish on pharma in general, but have no idea when business performance will be reflected in the stock prices. It's quite likely that PFE will rise in my rankings following the 4th quarter report.Sorry that's pretty superficial, but I don't get too in-depth in my analysis.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra